A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer

NCT06747338 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Early or Locally Advanced HER2-positive Breast Cancer

Interventions

DRUG: KN026
DRUG: HB1801
DRUG: Pertuzumab
DRUG: Trastuzumab
DRUG: Docetaxel
DRUG: Carboplatin

Sponsor

Shanghai JMT-Bio Inc.